MSDand Samsung Bioepis enter collaboration agreement to develop and commercialize insulin glargine candidate for diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.

“We look forward to collaborating with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company,” said Matt Strasburger, senior vice president, Diabetes, Global Human Health, MSD. “MSD is strengthening its leadership in diabetes through our own work and in collaboration with others, and this agreement will help build our portfolio across the spectrum of the disease.”

“Samsung Bioepis is very pleased to extend the partnership with MSD to the field of diabetes,” said Christopher Hansung Ko, Ph.D., CEO of Samsung Bioepis. “This collaboration will bring better access to patients with diabetes worldwide.”

Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, MSD will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.